Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2326 - 2350 of 14978 in total
Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. It is a fully human immunoglobulin, k-light-chain made in recombinant Chinese Hamster Ovary cells. It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical...
Approved
Investigational
Matched Description: … [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare ... hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Human Rho(D) immune globulin is a medicine given by intramuscular or intravenous injection that is used to prevent the immunological condition known as Rh disease (or hemolytic disease of newborn). Rho (D) immune globulin is available as a sterile, lyophilized or liquid gamma globulin (IgG) fraction containing antibodies to the...
Approved
Investigational
Matched Description: … Immune globullin was purified via ion-exchange chromatography method and prepared from pools of human …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Thyroglobulin (also known as Tg) is an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and triiodothyronine (T3). The active form of thyroxine, triiodothyronine, is produced both within the thyroid gland and periphery by 5'-deiodinase. Patients with Hashimoto's thyroiditis or Graves' disease, frequently...
Approved
Withdrawn
Matched Description: … an enzyme thyroid hormone used by the thyroid gland to produce the thyroid hormones thyroxine (T4) and ... The active form of thyroxine, triiodothyronine, is produced both within the thyroid gland and periphery …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. The pancrelipase amylase is a...
Approved
Matched Description: … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and ... mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and ... [T177] The pancrelipase amylase is a single polypeptide chain containing two SH groups and four disulfide …
Matched Categories: … Enzymes and Coenzymes …
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins …
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb. Nivolumab was...
Approved
Matched Description: … [L12129] This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region ... with the mutation _S228P_ for additional stability and reduced variability. …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV)...
Approved
Investigational
Matched Description: … It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. ... There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and...
Approved
Investigational
Matched Description: … starches and oligo-, tri-, and disaccharides into absorbable simple sugars. ... the subsequent postprandial increase in blood glucose and insulin levels. ... It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal …
Matched Categories: … metformin and acarbose ... Alimentary Tract and Metabolism …
CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.[A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), mediated by...
Approved
Investigational
Matched Description: … and autoimmune conditions. ... CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers ... A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis optica spectrum disorder (NMOSD).[A214283, A214286] Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody directed against the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic,...
Approved
Investigational
Matched Description: … Inebilizumab is cytolytic, resulting in B-cell depletion and offering therapeutic benefit to patients ... [L14315] Given its mechanism of action and good safety profile, it may prove useful in the treatment …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA...
Approved
Investigational
Matched Description: … tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive ... disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and ... Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Ravulizumab is a potent and selective complement 5 (C5) inhibitor. It is a humanized monoclonal IgG2/4 kappa antibody produced in Chinese hamster ovary (CHO) cells. Ravulizumab was engineered from eculizumab, another complement inhibitor, to increase the duration of action and reduce the frequency of drug administration. It works by blocking...
Approved
Investigational
Matched Description: … Ravulizumab is a potent and selective complement 5 (C5) inhibitor. ... atypical hemolytic uremic syndrome in children and adults. ... was engineered from [eculizumab], another complement inhibitor, to increase the duration of action and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand name Nexobrid [FDA Label]. Bromelain itself belongs to a category of protein-digesting enzymes that are...
Approved
Investigational
Matched Description: … Although both fruit and stem bromelain are prepared differently and contain different enzymatic compositions ... The primary therapeutic use for which stem bromelain is currently and formally indicated is as a burn ... wound eschar debridement agent that has been approved by the EMA since 2012 and marketed under the brand …
Matched Categories: … Enzymes and Coenzymes …
Tofersen is under an intrathecally administered antisense oligonucleotide targeting the mutated SOD1 gene that causes amyotrophic lateral sclerosis (ALS). Although there were various causes of ALS, 2% of ALS cases are due to SOD1 mutations, with more than 200 SOD1 mutations documented.[A259028,A259033] Tofersen was granted accelerated approval from the FDA...
Approved
Investigational
Matched Description: … [A259023] However, it could potentially be due to the short timeframe of tofersen treatment, and more ... [L46133] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament …
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan...
Approved
Matched Description: … in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and ... chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia...
Approved
Matched Description: … pharmacokinetic profile and conditions of use. ... than 20% in many readily used chemotherapy regimens,[A248855] infections pose risks of hospitalization and ... Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated...
Approved
Investigational
Matched Description: … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and ... [A262919] Tislelizumab is generally well tolerated with manageable and mild-to-moderate adverse effects …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Retifanlimab is a humanized IgG4 kappa monoclonal antibody that binds to the programmed death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2). By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune response against cancer cells. Other monoclonal...
Approved
Investigational
Matched Description: … By blocking the PD-1/PD-L1/2 pathway, retifanlimab potentiates T-cell activity and boosts the immune ... death receptor-1 (PD-1), blocking PD-1 interaction with its ligands, programmed death-ligand 1 (PD-L1) and ... [L45603] Other monoclonal antibodies that block PD-1 include [pembrolizumab], [nivolumab] and [cemiplimab …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas. It is commonly known as American Trypanosomiasis. The CDC estimates that approximately 8 million people in Central America, South America, and Mexico are infected with T. cruzi, without...
Approved
Investigational
Matched Description: … a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and ... L15366] The CDC estimates that approximately 8 million people in Central America, South America, and
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …
Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.[A38676, L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and breakthrough...
Approved
Investigational
Matched Description: … , L4840] The approval of emapalumab was followed by the designation of orphan drug, priority review and ... Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Approved
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-humanized CD20 antibodies such as rituximab, ocrelizumab is...
Approved
Investigational
Matched Description: … inflammatory, autoimmune disease of the central nervous system that leads to neurological disabilities and ... Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and ... In phase 3 clinical trials of patients with PPMS, treatment with ocrelizumab led to lower clinical and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the...
Approved
Matched Description: … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). …
Matched Categories: … Alimentary Tract and Metabolism ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with Mycobacterium tuberculosis...
Approved
Matched Description: … minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and
Matched Categories: … Indicators and Reagents ... Amino Acids, Peptides, and Proteins …
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826)
Approved
Matched Description: … A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. …
Matched Categories: … polythiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Displaying drugs 2326 - 2350 of 14978 in total